Article Versions Notes

Wieczorek A, Żebrowska U, Ussowicz M, Sokół A, Stypińska M, Dembowska-Bagińska B, Pawińska-Wąsikowska K, Balwierz W. Dinutuximab Beta Maintenance Therapy in Patients with High-Risk Neuroblastoma in First-Line and Refractory/Relapsed Settings—Real-World Data. Journal of Clinical Medicine. 2023; 12(16):5252. https://doi.org/10.3390/jcm12165252

Wieczorek, Aleksandra, Urszula Żebrowska, Marek Ussowicz, Agnieszka Sokół, Marzena Stypińska, Bożenna Dembowska-Bagińska, Katarzyna Pawińska-Wąsikowska, and Walentyna Balwierz. 2023. "Dinutuximab Beta Maintenance Therapy in Patients with High-Risk Neuroblastoma in First-Line and Refractory/Relapsed Settings—Real-World Data" Journal of Clinical Medicine 12, no. 16: 5252. https://doi.org/10.3390/jcm12165252

Wieczorek, A., Żebrowska, U., Ussowicz, M., Sokół, A., Stypińska, M., Dembowska-Bagińska, B., Pawińska-Wąsikowska, K., & Balwierz, W. (2023). Dinutuximab Beta Maintenance Therapy in Patients with High-Risk Neuroblastoma in First-Line and Refractory/Relapsed Settings—Real-World Data. Journal of Clinical Medicine, 12(16), 5252. https://doi.org/10.3390/jcm12165252